• 1
    Bruggen P, Traversari C, Chomez P, Lurquin C, Plaen DE, Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science (Washington DC) 1997;254: 16437.
  • 2
    Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994;180: 34752.
  • 3
    Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vitro tumor rejection. Proc Natl Acad Sci USA 1994;91: 645862.
  • 4
    Brichard V, Pel A, Wölfel T, Wölfel C, Plaen DE, Lethé B, Coulie P, Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanoma. J Exp Med 1993;178: 48995.
  • 5
    Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183: 118592.
  • 6
    Peoples GE, Geodegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognized the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92: 4326.
  • 7
    Fisk B, Blevins TL, Wharton J, Ioannides C. Identification of an immunodominant peptide of HER2/neu proto-oncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes line. J Exp Med 1995;181: 210917.
  • 8
    Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997;89: 293300.
  • 9
    Correale P, Walmsley K, Zaremb S, Zhu M, Schlom J, Tsang KY. Generation of human cytotoxic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998;161: 318694.
  • 10
    Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998;187: 27788.
  • 11
    Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restructed Cytotoxic T lymphocytes in cancer patients. Cancer Res 1999;59: 405663.
  • 12
    Ito S, Shichijo S, Miyagi Y, Kobayashi T, Tsuda N, Yamada A, Saito N, Itoh K. Identification of SART3-derived peptides capable of inducing HLA-A2-restriced and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer 2000;88: 6339.
  • 13
    Gomi S, Nakao M, Niiya F, Imamura Y, Kawano K, Nishizaka S, Hayashi A, Sobao Y, Oizumi K, Ito K. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. J Immunol 1999;163: 49945004.
  • 14
    Tamura M, Nishizaka S, Maeda Y, Ito M, Harashima N, Harada M, Shichijo S, Ito K. Identification of Cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-ristricted and tumor-specific cytotoxic T lymphocytes. Jpn J Cancer Res 2001;92: 7627.
  • 15
    Nishizaka S, Gomi S, Harada K, Oizumi K, Itoh K, Shichijo S. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. Cancer Res 2000;60: 48307.
  • 16
    Harashima N, Tanaka K, Sasatomi T, Shimizu K, Miyagi Y, Yamada A, Tamura M, Yamana H, Ito K, Shichijo S. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. Eur J Immunol 2000;31: 32332.
  • 17
    Kawano K, Gomi S, Tanaka K, Tsuda N, Kamura T, Ito K, Yamada A. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor infiltrating lymphocytes of lung cancer. Cancer Res 2000;60: 35508.
  • 18
    Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000;97: 12198203.
  • 19
    Marchand M, Baren VB, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigen peptide encoded by MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80: 21930.
  • 20
    Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Prakhurst MR, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998;4: 3217.
  • 21
    Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schandendorf D. 1998. Vaccination of melanoma patients with peptide- or tumor lysate- pulsed dendritic cells. Nature Med 1998;4: 32832.
  • 22
    Valmori D, Dutoit V, Rubio-Goboy V, Chambaz C, Lienard D, Guillaume P, Romeo P, Cerottini JC, Rimoldi D. Frequent cytotoxic T-cell responses to peptide MAGE-A10254-262 in melanoma. Cancer Res 2001;61: 50912.
  • 23
    Gajewski TF, Fallarino F, Ashikari A, Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res 2001;7: 895s901s.
  • 24
    Pittet MJ, Speiser DE, Lienard D, Valmori D, Guillaume P, Dutoit V, Rimoldi D, Lejeune F, Cerottini JC, Romero P. Expansion and functional mutation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res 2001;7: 796s803s.
  • 25
    Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, Eriksen JA, Moller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G. Interdermal ras peptide vaccination with granulocyte-macropharge colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92: 44150.
  • 26
    Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME, Weber J. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunol 2001;24: 6678.
  • 27
    Cole P, Rodu B. Descriptive epidemiology: cancer statistics. In: Vincent TD Jr., Samuel H, Rosenberg SA. Cancer principles and practice of oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001. 22930.
  • 28
    The Research Group for Population-Based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1995: estimates based on data from nine population-based cancer registries. Jpn J Clin Oncol 2001;30: 31821.
  • 29
    Imanishi I, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and haprotype frequencies for HLA and complement loci in various ethnic groups. In: Proceedings of the 11th International Histocompatibilty Workshop and Conference. Oxford: Oxford University Press, 1992. 1065220.
  • 30
    Browning M, Krausa P. Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol Today 1996;17: 16570.
  • 31
    Ito M, Shichijo S, Tsuda N, Ochi M, Harashima N, Saito N, Itoh K. Molecular Basis of T cell-mediated recognition of pancreatic cancer cells. Cancer Res 2001;61, 203846.
  • 32
    Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H, et al. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTLs. J Immunol 2000;164: 256574.
  • 33
    Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 peptide based on independent binding of individual peptide side-chains. J Immunol 1994;152: 16375.
  • 34
    Rammensee HG, Friede T, Stevanovic S. MHC ligands and peptide motifs. Immunogenetics 1995;41: 178228.
  • 35
    Kanneganti GK, Manley ML, Manley JL. The 160-kD subunit of human cleavage-polyadenylation specificity factor coordinates pre-mRNA 3′-end formation. Gene Dev 1995;9: 267283.
  • 36
    Beyer K, Danfekar T, Keller W. RNA ligands selected by Cleavage and Polyadenylation Factor contain direct sequence motifs that function as downstream elements in 3′-end processing of pre-mRNA. J Biol Chem 1997;272: 2676979.
  • 37
    Schul W, Driel R, Jong L. A subset of Poly(A) Polymerase is concentrated at sites of RNA synthesis and is associated with domains enriched in splicing factors and poly(A) RNA. Exp Cell Res 1998;238: 112.
  • 38
    Schul W, Kraan I, Matera AG, Driel R, Jong L. Nuclear domains enriched in RNA 3′-processing factors associate with coiled bodies and histone genes in a cell cycle-dependent manner. Mol Biol Cell 1999;10: 381524.